News
PLRX
12.73
-0.47%
-0.06
Positive Developments in Pliant Therapeutics’ IPF Research Bolster Buy Rating
TipRanks · 2d ago
Pliant Therapeutics Reports Increased Losses and Strategic Focus
TipRanks · 2d ago
Pliant Therapeutics Presents Positive INTEGRIS-PSC Trial Data at The Liver Meeting® 2024
Barchart · 2d ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Barchart · 3d ago
Weekly Report: what happened at PLRX last week (1111-1115)?
Weekly Report · 3d ago
Promising Pipeline and Strong Financials Reinforce Buy Rating for Pliant Therapeutics
TipRanks · 11/11 11:55
Weekly Report: what happened at PLRX last week (1104-1108)?
Weekly Report · 11/11 09:03
Buy Rating on Pliant Therapeutics Driven by Promising Bexotegrast Developments and Strategic Market Positioning
TipRanks · 11/11 06:26
Pliant Therapeutics Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
Dow Jones · 11/08 17:08
HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target
Benzinga · 11/08 16:58
Positive Clinical Progress and Promising Data Support Buy Rating for Pliant Therapeutics
TipRanks · 11/08 14:36
Oppenheimer Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)
TipRanks · 11/08 14:06
RBC Capital Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
TipRanks · 11/08 12:09
3 Best Stocks to Buy Now, 11/8/2024, According to Top Analysts 
TipRanks · 11/08 11:20
Positive Outlook on Pliant Therapeutics: Strategic Developments and Financial Stability Support Buy Rating
TipRanks · 11/08 10:17
Pliant Therapeutics GAAP EPS of -$0.95
Seeking Alpha · 11/08 05:26
Pliant Therapeutics, Inc. Reports Financial Results for the Quarter Ended September 30, 2024
Press release · 11/08 04:14
Pliant Therapeutics (PLRX) Receives a Buy from TD Cowen
TipRanks · 11/08 03:45
BRIEF-Pliant Therapeutics Q3 Net Income USD -57.763 Million Vs. IBES Estimate USD -59.3 Million
Reuters · 11/07 21:05
Press Release: Pliant Therapeutics Provides -2-
Dow Jones · 11/07 21:05
More
Webull provides a variety of real-time PLRX stock news. You can receive the latest news about Pliant Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PLRX
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. Its lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The Company has initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF. It has also developed PLN-1474, a small molecule, selective inhibitor of αvß1 integrin for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis. It has initiated a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. The Company has a preclinical program, PLN-101325, targeting muscular dystrophies.